ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Investment Research

ADMA Biologics (NASDAQ:ADMAGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday, reports.

According to Zacks, “ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey. “

Separately, assumed coverage on shares of ADMA Biologics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from, the company has an average rating of “Buy” and a consensus target price of $5.00.

NASDAQ:ADMA opened at $1.99 on Thursday. The company has a quick ratio of 2.77, a current ratio of 6.87 and a debt-to-equity ratio of 0.72. The company has a market cap of $389.88 million, a P/E ratio of -3.75 and a beta of 1.17. ADMA Biologics has a fifty-two week low of $1.01 and a fifty-two week high of $2.63. The firm’s 50 day moving average is $1.77 and its two-hundred day moving average is $1.51.

ADMA Biologics (NASDAQ:ADMAGet Rating) last posted its quarterly earnings results on Thursday, March 24th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $26.38 million for the quarter, compared to the consensus estimate of $26.00 million. ADMA Biologics had a negative net margin of 88.51% and a negative return on equity of 61.23%. During the same quarter last year, the firm posted ($0.20) earnings per share. Research analysts forecast that ADMA Biologics will post -0.31 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Nuveen Asset Management LLC raised its stake in shares of ADMA Biologics by 54.1% in the 4th quarter. Nuveen Asset Management LLC now owns 10,612,600 shares of the biotechnology company’s stock valued at $14,964,000 after acquiring an additional 3,727,960 shares during the period. Stonepine Capital Management LLC acquired a new stake in ADMA Biologics during the 4th quarter valued at $13,975,000. Clearline Capital LP grew its holdings in ADMA Biologics by 749.7% during the 4th quarter. Clearline Capital LP now owns 6,350,694 shares of the biotechnology company’s stock worth $8,954,000 after acquiring an additional 5,603,249 shares in the last quarter. BlackRock Inc. grew its holdings in ADMA Biologics by 73.3% during the 4th quarter. BlackRock Inc. now owns 4,075,591 shares of the biotechnology company’s stock worth $5,746,000 after acquiring an additional 1,724,224 shares in the last quarter. Finally, Maven Securities LTD acquired a new position in ADMA Biologics during the 4th quarter worth $4,675,000. 32.16% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile (Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Read More

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.